Embremma

Eribulina 0.5mg is a medication used to treat breast cancer, specifically in patients with metastatic breast cancer whose tumors have expressed human epidermal growth factor receptor 2 (HER2) and who have progressed on prior therapy. It is an injectable medication that works by inhibiting the growth of cancer cells and slowing down the progression of the disease.

Composition:

Eribulina 0.5mg is a solution of Eribulin mesylate, a medication that is a halichondrin B analog.

Indications:

Eribulina 0.5mg is indicated for the treatment of:

• Metastatic breast cancer in patients whose tumors have expressed HER2 and who have progressed on prior therapy
• Locally advanced or metastatic breast cancer in patients who have progressed on prior therapy

Mechanism of Action:

Eribulin works by:

1. Inhibiting the growth of cancer cells by blocking the activity of microtubules
2. Interfering with the normal function of microtubules, which are essential for cell division
3. Inducing apoptosis (cell death) in cancer cells

Dosage and Administration:

The recommended dosage of Eribulina 0.5mg is:

• 1.4mg/m² administered as a 2-minute intravenous infusion every 21 days
• The dose should be adjusted based on the patient’s response to treatment and tolerability

Side Effects:

Common side effects of Eribulina 0.5mg include:

1. Fatigue
2. Nausea and vomiting
3. Diarrhea
4. Constipation
5. Abdominal pain
6. Muscle weakness
7. Hair loss

Serious side effects can include:

1. Cardiac toxicity (heart failure, arrhythmias)
2. Neutropenia (low white blood cell count)
3. Thrombocytopenia (low platelet count)
4. Anemia (low red blood cell count)
5. Gastrointestinal perforation (hole in the stomach or intestine)

Contraindications:

Eribulina 0.5mg is contraindicated in patients with:

1. Severe neutropenia (low white blood cell count)
2. Severe thrombocytopenia (low platelet count)
3. Severe anemia (low red blood cell count)
4. Severe cardiac disease

Precautions:

1. Patients with a history of cardiac disease should be closely monitored while receiving Eribulina 0.5mg.
2. Patients with a history of gastrointestinal disease should be closely monitored while receiving Eribulina 0.5mg.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of fatigue, nausea, or diarrhea.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.

As with any medication, it is important to consult with a healthcare professional before taking Eribulina 0.5mg, especially if you have a history of medical conditions, are taking other medications, or are pregnant or breastfeeding.